N/A
Completed N=3,719
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
Source: ClinicalTrials.gov NCT00483002 ↗Enrolled (actual)
3,719
Serious AEs
0.1%
Results posted
May 2012
Primary outcomePrimary: Percentage of Participants With 7-day Point Prevalence From Week 3 to Less Than Week 7 — 59.55 Percentage of participants
Summary
To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With 7-day Point Prevalence From Week 3 to Less Than Week 7 |
59.55 | — |
| PRIMARY Percentage of Participants With 7-day Point Prevalence From Week 7 to Less Than Week 11 |
73.29 | — |
| PRIMARY Percentage of Participants With 7-day Point Prevalence for at Least Week 11 |
77.02 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects selected for this study are those who would have been prescribed Champix tablets by the physician according to the subject's condition in usual clinical practice.
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT00483002). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.